Softwr

Healthcare · head to head

Rx30 vs Signant Health

Rx30 logo

Rx30

Healthcare

Long-established pharmacy management system for independents and small chains

From
On request
Rated
-
Full reviewWebsite
Signant Health logo

Signant Health

Healthcare

eCOA-first clinical trial platform that has grown outward into EDC, eConsent and televisits

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Rx30 shares ownership with PioneerRx, so the two are not the independent alternatives a shortlist implies, and roadmap priorities are set centrally; Signant Health no pricing is published, and the software licence is a minority of the real bill once instrument licensing, translations, device provisioning and services are added, so early budget estimates are routinely too low.
  • They diverge on capability: Rx30 covers Prescription processing, Signant Health covers eCOA and ePRO.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Rx30 and Signant Health actually diverge.

Attributes where Rx30 and Signant Health differ
AttributeRx30Signant Health
PlatformsWindows, WebWeb, iOS, Android

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Rx30

  • Prescription processing
  • Claims adjudication
  • Inventory and purchasing
  • Point of sale
  • Delivery management
  • Clinical documentation

Only in Signant Health

  • eCOA and ePRO
  • Unified platform
  • eConsent
  • Randomisation and supplies
  • TeleVisits
  • Rater training
  • Data surveillance
  • Instrument library

What people use each for

The jobs each tool is most often brought in to do.

Rx30

  • Independent pharmacies and small chains wanting a mature, widely-supported systemnot Signant Health
  • Operations relying on a broad set of wholesaler and PBM interfacesnot Signant Health
  • Pharmacies with significant front-end retail alongside dispensingnot Signant Health
  • Multi-store independents needing consistency across locationsnot Signant Health

Signant Health

  • A central nervous system or psychiatry trial where the primary endpoint is a rated scale and rater consistency decides the readoutnot Rx30
  • A global study needing an outcome instrument translated and linguistically validated across a dozen languagesnot Rx30
  • A decentralised or hybrid protocol combining televisits, eConsent and at-home patient reported outcomesnot Rx30
  • A sponsor consolidating separate eCOA, eConsent and randomisation vendors onto one platform to cut reconciliation worknot Rx30

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Rx30

  • Shares ownership with PioneerRx, so the two are not the independent alternatives a shortlist implies, and roadmap priorities are set centrally
  • The interface shows its age against newer entrants, and this is the most common objection in demonstrations
  • Pricing is not published, and total cost including hardware and interfaces needs to be requested explicitly
  • Windows-centric, with a cloud story less developed than newer competitors
  • US-only, tied to US insurance and regulatory requirements

Signant Health

  • No pricing is published, and the software licence is a minority of the real bill once instrument licensing, translations, device provisioning and services are added, so early budget estimates are routinely too low.
  • Linguistic validation is charged per instrument per language and is on the critical path to first patient in, so adding a country late in start-up produces both a cost and a schedule hit.
  • Provisioned participant devices bring logistics, replacement, shipping and cellular connectivity obligations that persist for the life of the trial and are frequently underestimated.
  • The EDC component is newer than the eCOA heritage, so sponsors with complex data management requirements often keep an incumbent EDC and lose the single-database benefit that justifies the platform.
  • It is priced and scoped for sponsor-grade trials, which makes it a poor fit for investigator-initiated or academic studies that need outcome collection without the services layer.

Pricing, plan by plan

Rx30

On request
  • Rx30$undefined/month
    • Prescription processing
    • Claims adjudication
    • Inventory

Signant Health

On request
  • SmartSignals Unified Platform$undefined/year
    • Priced per study through a sales process
    • Modules selected per protocol: EDC, eCOA, randomisation, eConsent, TeleVisits
    • Instrument licensing paid to scale owners on top of platform cost

Which should you pick?

Choose Rx30 if

  • You need prescription processing.
  • You work on Windows, Web.
  • You also want claims adjudication.
Rx30 review

Choose Signant Health if

  • You need ecoa and epro.
  • You work on Web, iOS, Android.
  • You also want unified platform.
Signant Health review

Questions people ask

Is Rx30 or Signant Health better?
Neither clearly leads. Rx30 starts at On request and Signant Health at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Rx30 or Signant Health?
Rx30 starts at On request and Signant Health at On request.
Does Rx30 or Signant Health run on more platforms?
Rx30 runs on Windows, Web. Signant Health runs on Web, iOS, Android.
What is Rx30 best used for?
Rx30 is most often used for independent pharmacies and small chains wanting a mature, widely-supported system, operations relying on a broad set of wholesaler and pbm interfaces, pharmacies with significant front-end retail alongside dispensing, multi-store independents needing consistency across locations. Of those, independent pharmacies and small chains wanting a mature, widely-supported system and operations relying on a broad set of wholesaler and pbm interfaces are not what Signant Health is typically brought in for.
What can Rx30 do that Signant Health cannot?
Rx30 covers Prescription processing, Claims adjudication, Inventory and purchasing, Point of sale. Signant Health covers eCOA and ePRO, Unified platform, eConsent, Randomisation and supplies.

Answered from the vendors’ own pages

Rx30: Is Rx30 the same company as PioneerRx?

Both are owned by RedSail Technologies. They are sold as separate products to overlapping markets, but roadmap decisions sit with one company, which is worth knowing before treating them as independent options.

Signant Health: What is Signant best at?

Electronic clinical outcome assessment, particularly rated scales in central nervous system and psychiatry trials, together with rater training and endpoint quality services.

Rx30: What does it cost?

Not published. Request the total including hardware, interfaces and training rather than the monthly software fee.

Signant Health: Is pricing published?

No. Everything is quoted per study, and instrument licences, translations and devices sit on top of the platform cost.

Rx30: Why do pharmacies stay on it?

Installed base maturity. The interfaces to wholesalers, PBMs and hardware are long established, and those are the things that quietly stop a pharmacy working when they break.

Signant Health: Can I use it only for eCOA?

Yes. The modules are selected per protocol, and many sponsors take eCOA and eConsent while keeping an existing EDC.

Rx30: How does it compare to PioneerRx?

PioneerRx is more aggressively developed around clinical services. Rx30 has the larger legacy base and broader front-end retail heritage. Same owner, different emphasis.

Signant Health: What drives the timeline?

Translation and linguistic validation of outcome instruments, which is per language per instrument and sits on the critical path to study start.

Rx30: Is it suitable for a small chain?

Yes, and that is one of its stronger cases. Multi-store consistency is better handled here than by the systems aimed purely at single independents.

Share

Related pages

More on Rx30

More on Signant Health

Keep looking

Other head to heads